این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Iranian Journal of Blood and Cancer، جلد ۸، شماره ۲، صفحات ۵۲-۵۵
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Preliminary Results of Allogenic Hematopoietic Stem Cell Transplantation of non-M3 Acute Myeloid Leukemia
چکیده انگلیسی مقاله Background: Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) is used as treatment of choice for patients with acute myeloid leukemia (AML). We aimed to evaluate the prognostic factors in 2-year overall survival of patients with non-M3 AML who underwent allogenic HSCT. Methods: This is a Cross sectional retrospective study. Demographic data and study of variables such as age, sex, complete remission status, Karnofsky performance status scale at baseline and at time of transplantation, occurrence of GVHD (acute and chronic), relapse and 2-year survival were extracted from records of 49 patients who underwent allogenic HSCT from years 2006-2013 at BMT center in Imam Khomeini Hospital. All Autologous SCTs and M3 cases were not included. All data were analyzed with SPSS software. P< 0.05 was considered as statistically significant. Results: The overall survival rate was 55% in the patients. There was no significant difference in overall survival between complete remission (CR) 1 and CR2. Relapse rate was 6%. Mean 2-year Karnofsky scale was 93.7. Mean admission time following BMT was 22 days which was significantly related to 2-year performance status (P=0.02). Admission complication rate was 22.5% (GVHD 12%). Rate of overall GVHD was 55%, 40% of whom developed chronic GVHD which had a positive effect on 2-year overall survival (OS2).The patient's first performance state (K1) had a significant correlation with 2-year performance state (P< 0.05) and OS2 (P< 0.05). Conclusion: Chronic GVHD and initial Karnofsky performance status scale can be considered as good prognostic factors in patients with AML who undergo allo-HSCT.
کلیدواژه‌های انگلیسی مقاله
نویسندگان مقاله فرهاد شاهی | farhad shahi
department of hematology and medical oncology, cancer research center, cancer institute, imam khomeini hospital complex, tehran university of medical sciences, tehran, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (Tehran university of medical sciences)

مرضیه قلمکاری | marziye ghalamkari
internal medicine resident, imam khomeini hospital complex, tehran university of medical sciences, tehran, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (Tehran university of medical sciences)

سید رضا صفایی | seyed reza safayi
department of hematology and medical oncology, cancer research center, cancer institute, imam khomeini hospital complex, tehran university of medical sciences, tehran, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (Tehran university of medical sciences)

مهرزاد میرزانیا | mehrzad mirzania
department of hematology and medical oncology, cancer research center, cancer institute, imam khomeini hospital complex, tehran university of medical sciences, tehran, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (Tehran university of medical sciences)

مهدی khatuni | mahdi khatuni
internal medicine resident, imam khomeini hospital complex, tehran university of medical sciences, tehran, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (Tehran university of medical sciences)

فایزه الماسی | faeze almasi
internal medicine resident, imam khomeini hospital complex, tehran university of medical sciences, tehran, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (Tehran university of medical sciences)

نشانی اینترنتی http://www.ijbc.ir/browse.php?a_code=A-10-257-1&slc_lang=en&sid=en
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده 0|
نوع مقاله منتشر شده 1
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات